OPK

OPKO Health, Inc. [OPK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

OPK Stock Summary

Top 10 Correlated ETFs

OPK


Top 10 Correlated Stocks

OPK


In the News

11:01 28 Mar 2024 OPK

OPKO Health (OPK) And Entera Bio Announce Data for GLP-2

OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.

10:06 28 Mar 2024 OPK

OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.

08:31 28 Mar 2024 OPK

OPKO Health (OPK) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

08:08 28 Mar 2024 OPK

OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript

OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript

07:10 28 Mar 2024 OPK

OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates

OPKO Health (OPK) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago.

04:05 28 Mar 2024 OPK

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Tuesday, February 27, 2024. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on February 27th beginning at 4:30 p.m. Eastern time.

11:48 28 Mar 2024 OPK

3 Stocks with Major Insider Buying This Month

Active traders use many fundamental or technical signals to set up their trades. Stocks exhibiting heavy insider buying can be one of these signals.

10:49 28 Mar 2024 OPK

More Big Warren Buffett Purchases Highlight Recent Insider Buying

The number of notable insider purchases in mid-January may have been somewhat small, but a couple from the Oracle of Omaha made headlines.

12:02 28 Mar 2024 OPK

Here's Why You Should Retain OPKO Health (OPK) Stock for Now

OPKO Health's (OPK) potential in Rayaldee raises optimism about the stock.

12:02 28 Mar 2024 OPK

OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall third-quarter results reflect soft performances.

OPK Financial details

Company Rating
Neutral
Market Cap
672.32M
Income
-188.85M
Revenue
863.52M
Book val./share
1.85
Cash/share
0.13
Dividend
-
Dividend %
-
Employees
3.93K
Optionable
Yes
Shortable
Yes
Earnings
01 May 2024
P/E
-3.77
Forward P/E
-4.7
PEG
0.82
P/S
0.93
P/B
0.54
P/C
9.04
P/FCF
-19.56
Quick Ratio
1.28
Current Ratio
1.78
Debt / Equity
0.19
LT Debt / Equity
0.16
-
-
EPS (TTM)
-0.25
EPS next Y
-0.25
EPS next Q
-0.09
EPS this Y
-45.65%
EPS next Y
2.09%
EPS next 5Y
-130.14%
EPS last 5Y
-13.63%
Revenue last 5Y
-0.87%
Revenue Q/Q
1.85%
EPS Q/Q
-19.55%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
19.4%
Inst Trans
0.86%
ROA
-10%
ROE
-14%
ROC
-0.08%
Gross Margin
38%
Oper. Margin
-17%
Profit Margin
-24%
Payout
-
Shs Outstand
696.99M
Shs Float
327.73M
-
-
-
-
Target Price
3.5
52W Range
0.85-2.24
52W High
-
52W Low
-
RSI
66
Rel Volume
0.7
Avg Volume
14.04M
Volume
9.8M
Perf Week
32.07%
Perf Month
15.24%
Perf Quarter
-22.67%
Perf Half Y
-26.54%
-
-
-
-
Beta
1.797
-
-
Volatility
0.07%, 0.07%
Prev Close
9.85%
Price
1.1754
Change
17.54%

OPK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.512.242.741.41.15
Net income per share
-0.520.05-0.05-0.46-0.25
Operating cash flow per share
-0.290.060.06-0.13-0.04
Free cash flow per share
-0.310.010.01-0.17-0.06
Cash per share
0.140.110.210.210.13
Book value per share
2.712.612.62.171.85
Tangible book value per share
-0.54-0.440.080.24-0.19
Share holders equity per share
2.712.612.62.171.85
Interest debt per share
0.430.440.360.310.37
Market cap
875.32M2.53B3.12B898.83M1.14B
Enterprise value
1B2.68B3.17B959.13M1.37B
P/E ratio
-2.8182.74-105.67-2.74-6.01
Price to sales ratio
0.971.761.760.91.31
POCF ratio
-5.0764.181.31-9.44-40.26
PFCF ratio
-4.72436.76504.33-7.5-25.53
P/B Ratio
0.541.511.850.580.82
PTB ratio
0.541.511.850.580.82
EV to sales
1.111.871.790.961.58
Enterprise value over EBITDA
-18.4425.261.22K-5.38-25.89
EV to operating cash flow
-5.867.982.7-10.08-48.44
EV to free cash flow
-5.4462.61512.94-8.01-30.71
Earnings yield
-0.360.01-0.01-0.36-0.17
Free cash flow yield
-0.2100-0.13-0.04
Debt to equity
0.150.150.130.140.19
Debt to assets
0.10.10.090.10.13
Net debt to EBITDA
-2.321.4120.46-0.34-4.37
Current ratio
1.31.392.731.851.55
Interest coverage
-9.142.63-2.53-20.42-11.7
Income quality
0.551.29-1.270.290.15
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.130.050.040.070.1
Intangibles to total assets
0.550.510.460.360.76
Capex to operating cash flow
0.07-0.85-0.840.260.58
Capex to revenue
-0.01-0.02-0.02-0.02-0.02
Capex to depreciation
-0.14-0.39-0.41-0.23-0.15
Stock based compensation to revenue
0.010.010.010.020.01
Graham number
5.651.671.634.723.23
ROIC
-0.110.02-0.05-0.11-0.09
Return on tangible assets
-0.30.03-0.02-0.24-0.39
Graham Net
-0.78-0.68-0.52-0.42-0.53
Working capital
74.9M147.7M521.2M181M109.42M
Tangible asset value
352.7M400.8M574.3M770.7M-144.32M
Net current asset value
-370.5M-278.3M108.4M-211.2M-313M
Invested capital
0.150.150.130.140.19
Average receivables
159.84M229.97M283.92M207.1M139.4M
Average payables
54.97M81.71M91.46M74.52M68.34M
Average inventory
47.87M92.89M109.42M80.28M69.88M
Days sales outstanding
63.8276.8654.6254.0255.04
Days payables outstanding
39.8741.1725.134.1640.28
Days of inventory on hand
34.0754.0126.4637.7537.98
Receivables turnover
5.724.756.686.766.63
Payables turnover
9.158.8714.5410.699.06
Inventory turnover
10.716.7613.799.679.61
ROE
-0.190.02-0.02-0.21-0.14
Capex per share
-0.02-0.05-0.05-0.03-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.250.320.350.240.24
Net income per share
-0.11-0.02-0.03-0.11-0.09
Operating cash flow per share
-0.04-0.0300.04-0.05
Free cash flow per share
-0.05-0.03-0.010.04-0.05
Cash per share
0.20.150.140.180.13
Book value per share
2.082.062.041.921.85
Tangible book value per share
0.230.2-0.050.12-0.19
Share holders equity per share
2.082.062.041.921.85
Interest debt per share
0.290.320.40.330.36
Market cap
937.71M1.1B1.63B1.2B1.13B
Enterprise value
998.01M1.2B1.82B1.28B1.37B
P/E ratio
-2.75-15.07-20.76-3.56-4.27
Price to sales ratio
5.064.626.156.736.24
POCF ratio
-29.66-48.45-4.47K36.32-29.63
PFCF ratio
-24.71-42.72-255.7641.6-27.47
P/B Ratio
0.60.711.060.830.82
PTB ratio
0.60.711.060.830.82
EV to sales
5.385.046.857.157.51
Enterprise value over EBITDA
-24.16-134.57137.81-28.32-31.67
EV to operating cash flow
-31.56-52.89-4.98K38.57-35.66
EV to free cash flow
-26.29-46.63-285.1744.18-33.05
Earnings yield
-0.09-0.02-0.01-0.07-0.06
Free cash flow yield
-0.04-0.0200.02-0.04
Debt to equity
0.140.160.190.180.19
Debt to assets
0.10.110.140.120.13
Net debt to EBITDA
-1.46-11.2914.21-1.66-5.35
Current ratio
1.851.831.921.781.55
Interest coverage
-17.98.992.1419.03-20.01
Income quality
0.371.240.02-0.390.58
Dividend Yield
00000
Payout ratio
-0.010000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.110.140.070.110.11
Intangibles to total assets
0.360.370.730.380.76
Capex to operating cash flow
0.20.1316.47-0.130.08
Capex to revenue
-0.03-0.01-0.02-0.02-0.02
Capex to depreciation
-0.24-0.11-0.23-0.16-0.12
Stock based compensation to revenue
0.020.010.010.020.01
Graham number
2.311.061.12.211.92
ROIC
-0.03-0.020-0.04-0.04
Return on tangible assets
-0.06-0.01-0.03-0.07-0.14
Graham Net
-0.41-0.5-0.41-0.47-0.53
Working capital
181M184M207.34M156.6M109.42M
Tangible asset value
770.7M759.4M-39.22M655.1M-144.32M
Net current asset value
-211.2M-211.4M-189.76M-254.9M-313M
Invested capital
0.140.160.190.180.19
Average receivables
143.43M135.05M174.79M172.77M123.82M
Average payables
58.37M73.75M84.19M77.34M68.24M
Average inventory
72.74M74.74M74.58M71.35M67.33M
Days sales outstanding
72.1446.0277.3459.1864.42
Days payables outstanding
46.652.3956.9245.9339.51
Days of inventory on hand
51.5149.0747.7747.4137.26
Receivables turnover
1.251.961.161.521.4
Payables turnover
1.931.721.581.962.28
Inventory turnover
1.751.831.881.92.42
ROE
-0.05-0.01-0.01-0.06-0.05
Capex per share
-0.010-0.01-0.010

OPK Frequently Asked Questions

What is OPKO Health, Inc. stock symbol ?

OPKO Health, Inc. is a US stock , located in Miami of Fl and trading under the symbol OPK

Is OPKO Health, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $3.5. The lowest prediction is $3 and the highest is $4

What is OPK stock prediction ?

What is OPKO Health, Inc. stock quote today ?

OPKO Health, Inc. stock price is $1.1754 today.

Is OPKO Health, Inc. stock public?

Yes, OPKO Health, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap